文献速递膀胱癌与上尿路尿路上皮癌

变异组织学是否改变非肌层浸润性膀胱癌的管理

Does Variant Histology Change Management of Non-muscle-invasive Bladder Cancer?
PubMed 文献 · Eur Urol Oncol · 2019-08-06

本文以一例52岁男性吸烟患者为例,其两处非肌层浸润性尿路上皮肿瘤(pTa和pT1)经参考病理学家复核后,pTa被升级为pT1,且两处均定义为微乳头状癌。文章探讨了「变异组织学」的重要性及参考病理学家诊断微乳头状变异是否真正需要改变治疗策略。

要点

  • 参考病理学家将两处肿瘤分别诊断为pTa和pT1,怀疑变异后请第二位病理学家复核。
  • 第二位病理学家将较轻肿瘤升级为T1,两处均定义为微乳头状癌。
  • 讨论内容包括膀胱切除与尝试保留膀胱治疗两种策略的选择。

核心结论

  • 文章以病例形式讨论变异组织学是否改变非肌层浸润性膀胱癌的管理,以及参考病理学家诊断微乳头状变异是否真正需要改变治疗策略。

研究设计与样本

  • 本文为病例讨论,患者为52岁男性,35包年吸烟者,诊断为两处非肌层浸润性尿路上皮肿瘤(pTa和pT1)。

主要发现

  • 参考病理学家将两处肿瘤分别诊断为pTa和pT1,怀疑变异后请第二位病理学家复核,后者将较轻肿瘤升级为T1,两处均定义为微乳头状癌。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 52-yr-old man, 35 pack-year smoker, is diagnosed with two non-muscle-invasive urothelial tumors, pTa and pT1, the former upstaged to pT1 by a reference pathologist. Two possible treatment strategies include intravesical bacillus Calmette-Guérin (BCG) and/or primary or rescue cystectomy. The importance or even accurate existence of "variant histology" is put into perspective, and whether the reference pathologist's diagnosis of a micropapillary variant requires a real change in treatment strategy is considered. PATIENT SUMMARY: The reference urologist diagnosed two small bladder tumors as two different depths of infiltration: one as pTa and the other (slightly more severe) as pT1. Suspecting a variant, the reference urologist referred to a second pathologist, who upstaged the less severe tumor to T1, with both defined as micropapillary cancer. This presentation discusses removal of the bladder versus a trial of treatment with bladder preservation.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Burger M, Kamat AM, McConkey D, et al. Does Variant Histology Change Management of Non-muscle-invasive Bladder Cancer? Eur Urol Oncol. 2019. PMID: 31395481. doi:10.1016/j.euo.2019.06.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。